Fig. 6.

Combined effect of PLX4720 and autophagy inhibitors on cell survival. In (A) and (B), A375P, SK-MEL-2, and their ATG5 KO cells were treated with 1 μM of PLX4720 (A) or trametinib (B). Whole-cell lysates were immunoblotted with antibodies to phospho-ERK, ERK, phospho-MEK and MEK. In (C-F), A375P, SK-MEL-2, and their ATG5 KO cells were treated with increasing concentrations of PLX4720 (C), trametinib (D), SBI-0206965 (E), or HCQ (F). Cell viability was determined using the WST-1 assay. All values are relative to the vehicle control and are presented as mean ± SD (n=4).